ESMO-BC 2023 - ESMO Breast Cancer Annual Congress
May 11 - May 13, 2023 | BerlinGermany
LARVOL is not affiliated with ESMO Breast Cancer Annual Congress and all trademarks, logos, and brand names are property of their respective owners
Showing 98 abstracts linked to Trials
Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): a detailed safety analysis of the randomized, phase 3 DESTINY-Breast04 trial
Discussion
Proffered Paper session 1Capivasertib and fulvestrant for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2- advanced breast cancer (ABC): subgroup analyses from the Phase 3 CAPItello-291 trial
Discussion
Proffered Paper session 1Final analysis of the placebo-controlled randomised phase 3 IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC)
Discussion
Proffered Paper session 2HER2DX and pathological complete response in HER2-positive breast cancer: a combined analysis of 4 neoadjuvant studies
Discussion
Mini Oral session 2HER2 expression and early response to patritumab deruxtecan (HER3-DXd) in early-stage hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC): a correlative analysis from SOLTI-TOT-HER3 trial
Discussion
Mini Oral session 2DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with human epidermal growth factor 2 (HER2)-low, estrogen-receptor (ER) expression immunohistochemistry (IHC) 0-10% metastatic breast cancer (mBC)
Discussion
Mini Oral session 2Patient-reported outcomes (PROs) from DESTINY-Breast02, a randomized phase 3 study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC)
Discussion
Proffered Paper session 1EMERALD trial analysis of patient-reported outcomes (PROs) in patients with ER+/HER2_ advanced or metastatic breast cancer (mBC) comparing oral elacestrant vs standard of care (SoC) endocrine therapy
Discussion
Proffered Paper session 1Circulating tumor DNA (ctDNA) dynamics in patients (pts) receiving capecitabine (CAPE) for early-stage triple-negative breast cancer (eTNBC) with an incomplete response to neoadjuvant therapy (NAT)
Discussion
Mini Oral session 2A phase 2 Study of Patritumab Deruxtecan (HER3-DXd), in patients (pts) with advanced breast cancer (ABC), with biomarker analysis to characterize response to therapy (ICARUS-BREAST01)
Discussion
Proffered Paper session 2Long-term patient-reported outcomes from monarchE: abemaciclib plus endocrine therapy for adjuvant HR+, HER2-, node-positive, high-risk, early breast cancer (EBC)
Discussion
Mini Oral session 1Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple negative breast cancer (TNBC): results of part B of SOLTI TOT-HER3 window of opportunity trial
Discussion
Proffered Paper session 2KEYNOTE-355: Outcomes in patients who discontinued chemotherapy before pembrolizumab and in patients with immune-mediated AEs
Discussion
Mini Oral session 1The prognostic and predictive effect of BMI in postmenopausal HR+ breast cancer patients receiving (extended) endocrine therapy - DATA trial analysis
Discussion
Mini Oral session 1Development of a Deep Learning model using a large real-world database to predict overall survival in patients with metastatic breast cancer (MBC)